ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG CỦA BỆNH NHÂN UNG THƯ BIỂU MÔ TUYẾN GIÁP BIỆT HÓA KHÁNG 131I TẠI BỆNH VIỆN TRUNG ƯƠNG THÁI NGUYÊN

Abstract

Objective: To investigate some clinical, subclinical characteristics of radioiodine refractory differentiated thyroid carcinoma patients at Thai Nguyen National Hospital.              

Materials and method: A prospective descriptive study was conducted on 55 differentiated thyroid carcinoma patients treated with ¹³¹I post-total thyroidectomy and were defined to be radioiodine refractory at Thai Nguyen National Hospital from May 2019 to May 2024.               

Results: The average age of the patients was 47.8 ± 11.3, 87.3% were female. 90.9% of patients were papillary thyroid carcinoma. The proportion of patients in stages I, II, III and IV were 43.6%, 27.3%, 7.3% and 21.8% respectively. 81.8% of patients had intermediate and high risk of recurrence. The mean total dose of ¹³¹I treated was 345.5 ± 132.4 mCi and the ¹³¹I treatment courses were 2.24 ± 1.1. Patients’ serum stimulated Tg levels were still high at the time radioiodine refractory was detected. The rate of patients in groups 1, 2, 3 and 4 were 52.7%, 21.8%, 9.1% and 16.4% respectively according to ATA 2015 radioiodine refractory classification of differentiated thyroid carcinoma (DTC). 72.7% of patients had one radioiodine refractory lesion, 85.5% had radioiodine refractory lesions in cervical lymph nodes or cervical lymph nodes combined with other locations.                Conclusion: Radioiodine refractory differentiated thyroid carcinoma (RR-DTC) was common in patients with intermediate or high risk of recurrence. Most malignant and metastatic tissues did not concentrate radioactive iodine from the first or after treatment courses. Radioiodine refractory lesions were often found in cervical lymph nodes or in combination with other locations.